From the Guidelines
A single 300mg IV dose of Venofer (iron sucrose) typically increases hemoglobin by approximately 1 g/dL over several weeks, though individual responses vary. This increase occurs gradually as the body incorporates the supplemental iron into new red blood cells. Venofer works by replenishing iron stores, which are essential for hemoglobin production. The full hemoglobin response may take 2-4 weeks to develop as the bone marrow uses the iron to produce new red blood cells. Factors affecting the response include the severity of initial iron deficiency, underlying conditions causing blood loss, kidney function, and inflammation status. According to the most recent study 1, in anemic patients, hemoglobin levels should increase by 1 g/dL within 2 weeks of supplementation. Patients should be monitored with follow-up blood tests to assess the hemoglobin response, and additional doses may be needed depending on the clinical situation and the target hemoglobin level. Side effects of Venofer may include hypotension, nausea, and injection site reactions.
Some key points to consider when using Venofer include:
- The dosage and frequency of administration, as different formulations of IV iron are available 1
- The potential for idiosyncratic infusion reactions, which can mimic allergic reactions 1
- The importance of monitoring patients for response to treatment and adjusting the dose as needed 1
Overall, the use of Venofer for iron deficiency anemia is supported by recent clinical guidelines 1, and its effectiveness in increasing hemoglobin levels makes it a valuable treatment option for patients who cannot tolerate oral iron or have not responded to oral iron supplementation.
From the FDA Drug Label
Patients in the Venofer / erythropoietin group had statistically significantly greater mean change from baseline to the highest hemoglobin value (1.3 g/dL), compared to subjects who received erythropoietin alone (0.6 g/dL) (p < 0.01).
The administration of 300mg IV Venofer increases hemoglobin by 1.3 g/dL 2.
From the Research
Hemoglobin Increase with 300mg IV Venofer
- The provided studies do not directly address the specific question of how many hemoglobin points 300mg IV Venofer increases hemoglobin by.
- However, study 3 discusses the safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease, which may be relevant to understanding the effects of IV iron supplementation on hemoglobin levels.
- Study 3 found that intravenous iron sucrose 500 mg infused over three hours on two consecutive days increased transferrin saturation and serum ferritin in iron-deficient, anemic CKD patients, but does not provide specific data on hemoglobin increase.
- Other studies, such as 4, 5, and 6, discuss the use of intravenous iron supplementation in chronic kidney disease, but do not provide specific information on the hemoglobin increase associated with 300mg IV Venofer.
- Study 7 evaluates the effects of iron on cardiovascular, kidney, and safety outcomes in patients with CKD, but does not provide specific data on hemoglobin increase associated with IV iron supplementation.
Available Data on Hemoglobin Increase
- None of the provided studies directly report the increase in hemoglobin points associated with 300mg IV Venofer.
- Study 5 reports a mean increase in hemoglobin of 14.65% in the IV group, but this is not specific to 300mg IV Venofer and is based on a different iron formulation.
- Study 6 mentions a meta-analysis that found a mean increase in hemoglobin with intravenous iron of only 0.31 g/dL compared to oral iron, but this is not specific to 300mg IV Venofer and is based on a comparison with oral iron.